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Background: Muscle fatigue, weakness and atrophy are basilar clinical features that accompany facioscapulohumeral
dystrophy (FSHD) the third most common muscular dystrophy.
No therapy is available for FSHD.
Case presentation: We describe the effects of 6mo exercise therapy and nutritional supplementation in a 43-year-old
woman severely affected by FSHD.
Conclusion: A mixed exercise program combined with nutritional supplementation can be safely used with beneficial
effects in selected patients with FSHD.
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Selective muscle atrophy with weakness and early fatigue
[1] are main features of facioscapulohumeral dystrophy
(FSHD), the third most common muscular dystrophy
(MD).
No therapy is available for FSHD. Nevertheless, pa-
tients usually report some improvement related to phys-
ical exercise and the use of nutritional supplements
(NS). These effects are not currently substantiated by
appropriate investigations. In particular the effect of ex-
ercise training has not been fully examined mainly due
to concerns that it may trigger disease progression.
However recent observations suggest that in FSHD post-
exercise creatine kinase (CK) elevation (indicator of
muscle damage) normalizes within one day compared with
the pre-exercise values [2].
Again, the role of NS in MD remains to be elucidated.
Recent observations suggest that among supplements
creatine and Branched Chain Amino Acids (BCAA)
may exert positive effects as they may act by limiting* Correspondence: gdantona@unipv.it
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unless otherwise stated.exercise-induced injury [3]. The positive changes due
to creatine appear to be safely enhanced by coadmin-
istration of conjugated linoleic acid (CLA) [4].
The aim of this case report is to show the effects of a
controlled exercise training and NS in a FSHD patient.
Case presentation
A 43-year-old wheelchair-bound woman from 2006, af-
fected by FSHD, underwent 6-month exercise therapy
associated with NS to study metabolic and possible
changes in motor function related to the program.
The patient was born from uneventful pregnancy and
delivery to non-consanguineous parents, with family his-
tory negative for MD.
The patient carries a “de novo” D4Z4 reduced allele
with 2 repeats (14 kb).
When she was 2 yrs her parents noted difficulty of
walking and waddling gait. At 4 she was diagnosed hav-
ing a muscle disease. At 11 she was clinically diagnosed
with a progressive MD. At 30 neurological examination
revealed left steppage gait, facial weakness, atrophy of
shoulder girdle muscles with bilateral scapular winging,
atrophy of bilateral pectoralis, infraspinatus and supras-
pinatus muscles, moderate biceps brachii and severe del-
toid weakness, foot extensor weakness and proximal hip
weakness, lumbar hyperlordosis; lower extremities tendon
reflexes were absent, sensory examination was normal. InLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ible with FSHD.
Presently she presents severe muscle hypotrophy and
proximal-distal weakness leading to loss of ambulation
in 2006 and severe lumbar hyperlordosis (FSHD score
12 according to Lamperti et al. [5]).
In 2001 respiratory function assessment first re-
vealed mild respiratory restrictive insufficiency (%pred:
VC 75.9; FVC 82.3; FEV1 88.50; FEV1%/VCmax 133, see
Figure 1).
Methods
The patient (180 cm, 71.4 Kg) participated in the study
after providing written informed consent. Procedures were
conducted according to the Declaration of Helsinki. The
protocol had a duration of 6 mo, 4 days/week. Before and
after exercise and nutrition intervention the following eval-
uations were performed:
Oxygen consumption
Considering that skeletal muscle metabolism is the major
determinant of resting energy expenditure (REE), we ex-
plored the impact of disease and training/supplementationFigure 1 Temporal change (from 1997 to 2012) of selected pulmonar
upper left; VC, lower left; FEV1, upper right; FEV1/VCmax, lower right
respiratory failure in 43y old FSHD patient. Dotted arrow indicates the
therapy protocol.on REE by indirect calorimetry (Quark b2, Cosmed) in su-
pine position (12 h fasting at 9.00 a.m.).
Endurance performance was evaluated with incremen-
tal stepwise ramp test (ISRT) on a handbike (Monark
Trainer 881E). After three minutes at rest the subject
exercised at 0 Watt as warm-up. Then the workload
was increased by 2.5 Watt/step with a step duration of
2.5-min until exhaustion (cadence 60 rpm). Gas flows
were continuously recorded breath-by-breath using the
Quark b2. Beat-by-beat heart rate (Polar RS400) and
ECG were monitored. Breath-by-breath data were aver-
aged per 10s at the end of each workload. Peak cardio-
respiratory responses were defined as the maximal
averaged values registered over 10s during the last test
stage [6]. Peak oxygen uptake (VO2peak), minute ventilation
(VE), and Borg score at 7.5 Watt are reported in Table 1.
Body composition
Whole body bioelectrical impedance analysis (BIA) was
made with a single frequency (50 kHz) analyzer (BIA-101,
RJL/Akern). Test-retest reliability was assessed in two sep-
arate measurements 2 h apart. Means and standard devia-
tions for all variables are reported in Table 1.y function tests expressed as percentage of predicted (FVC,
) showing the progression from mild to moderate restrictive
year of bound to wheelchair; solid arrow indicates the start of sport
Table 1 Body composition, blood and functional parameters before and intervention
Parameter Before After UM n.v.
Body composition
Body mass 71.4 62 Kg
BMI 21.9 ± 0.1 19.2 ± 0.1 % 18.5-24.9
TBW 33.8 ± 0.2 38.2 ± 0.3 % 55-62
ECW 50.2 ± 0.3 53.1 ± 0.1 % 40% TBW
ICW 50.3 ± 0.4 47.1 ± 0.2 % 60% TBW
FFM 64.2 ± 0.3 72.1 ± 0.1 % Min 75
FM 36.2 ± 0.2 28.1 ± 0.1 % Max 25
Blood parameters
HDL 42 46 mg/dc >43
Calcium 8.3 8.9 mg/dc 8.5-11
Total Proteins 5.9 6.6 g/dc 6-8
Albumin 52.5 56.6 % 55.8-66.1
Alpha1 globulin 5.5 4 % 2.9-4.9
Alpha2 globulin 12.7 11 % 7.1-11.8
Beta1 globulin 6.3 5.5 % 4.7-7.2
Beta2 globulin 4.9 4.4 % 3.2-6.5
Gamma globulin 18.1 18.5 % 11.1-18.8
A/G 1.11 1.3 - 1.26-1.95
Functional parameters
HR 68 65 b/min
HRpeak 143 141 b/min
REE 1358 1332 ml · min−1
VO2(7.5Watt) 11.76 7.9 ml/Kg/min
−1
VE 30 20 L/min
Borg Scale7.5Watt 17 14
Muscle district Right Left Right Left
Shoulder abductors 16,7* 21,6† 38.2* 39.2† N
Elbow flexors 25,5‡ 16,7‡ 20,6‡ 23,5‡ N
Elbow extensor 6,9‡ 12,7‡ 11,7‡ 10,7‡ N
BMI: body mass index; TBW: total body water; ECW: extracellular water; ICW: intracellular water; FFM: fat free mass; FM: fat mass; HDL: high density lipoprotein;
A/G: albumin globulin ratio. HR: heart rate; mHR: maximal heart rate (mHR = 206.9 – (0.67*age); REE: resting energy expenditure; VO2(7.5Watt): oxygen consumption
at 7.5 Watt load; VE: ventilation exchange; Isometric force in Newton; *23°; † 28°; ‡ 90°.
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Isometric strength (maximal voluntary contraction,
MVC) was quantified by means of a dynamometer
(Muscle Lab 4000E). The patient carried MVC of
the following groups: elbow flexors, elbow extensors,
shoulder abductors. Each trial lasted 3 s and the rest
time was of 30s and the mean peak force (Nm) was
calculated.
Spirometry
Pulmonary function tests (PFTs) were recorded by using
Cosmed Pony spirometer. The PFTs recorded before and
after training are reported in Table 1. Temporal change(from 1997 to 2012) of selected PFTs (FVC, VC, FEV1,
FEV1/VCmax) is described in Figure 1.
Blood analysis
Routine blood and urine analysis were performed before
and after treatment. Blood parameters changed after
intervention are reported in Table 1. No change in CK
levels was observed after training (initial value 87 U/L;
final value 86 U/L (n.v. 15–150).
Training
The patient underwent a mixed endurance/strength train-
ing. Heart rate was monitored during endurance sessions.
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2 time/wk strength). Endurance training on assisted arm
cycle ergometer (warm up, HR 90 min; work, 4 kCal/min
or HR 130 min−1): wk 1, 5 min warm up, 10 min work; wk
2–12, 5 min warm up, 15 min work; wk 13–24, 5 min
warm up, 20 min work. Strength training with green
Thera-band®: 8 repetition 2 series, 5 min rest between
series, for each muscular district. To obtain a load of 50-
60% of MVC the green Thera-band® was stretched of a
defined% of the initial length: for lateral abduction
the patient was instructed to stretch the Thera-band®
of about 50% of the band initial length, for biceps flexion
and triceps extension of about 25%. The sessions were per-
formed at patient’s home without supervision. Periodical
Skype® meetings were organized to verify the correct exe-
cution of training.
Respiratory muscle training consisted in 4 time/wk-
2 min sessions (50% vital capacity at 20 min−1) of isocap-
nic hyperpnea. Training was carried out with a device
(Spirotiger®) that operates on rebreathing principle [7].
Before training subject was instructed to keep the tidal
volume at 50% of the vital capacity and to follow the de-
vice metronome for frequency pacing.
Nutritional supplementation
Nutritional supplementation included BCAA enriched
mixture, creatine plus CLA.
The amino acid supplement consisted in a BCAA-
enriched formula with 2:1:1 leucine:isoleucine:valine
ratio (BigOne, Professional Dietetics), and already known
to exert beneficial effects on skeletal muscle [8-10]
(0.1 gr/kg/day in two doses at breakfast and dinner). Cre-
atine monohydrate (CreaATP, Syform, 0.1gr/day) was ad-
ministered in combination with CLA (Syform, 2.4 gr/day
corresponding to 3 pearls/day at breakfast or 2 h before
strength exercise) [11].
Results
At the end of the protocol we observed an improvement
of the patient’s nutritional status as demonstrated by sig-
nificant improvement of anthropometric (BMI, FFM)
and biochemical (serum proteins) parameters. In par-
ticular a reduction of body mass (−13.17%) associated
with reduced fat mass (FM, −8%) and improved fat free
mass (FFM +8%) was found (Table 1). Indeed beneficial
changes in biochemical blood parameters included in-
creased total protein concentration, albumin percentage,
and albumin/globulin ratio which were reported to nor-
mal values (Table 1). Functionally a modest increase of
peak force was observed only in shoulder abductors
bilaterally whereas no change was observed in elbow
flexors and extensors (Table 1). An amelioration of peak
oxygen consumption (VO2peak), ventilation exchange,
and an improvement of Borg score during submaximalexercise suggested the appearance of a certain degree of
muscular adaptation to training and possibly an amelior-
ation of the oxidative metabolism (Table 1). This was
demonstrated by increased time/power to exhaustion
during incremental test. Finally after intervention sub-
stantial steadiness of several PFTs in comparison with
initial evaluation (FVC before: 69.6, after 67.4; VC: 68.7
before, 70.4 after; FEV1 before 68.2; after 68.5; FEV1/
FVC% before 104.9, after 108.8) was observed (Figure 1).
Conclusions
Results from our report suggest that a specific exercise
therapy and supplementation program can be safely used
in selected FSHD patients but the relative contribution
of the adopted interventions, exercise and dietary sup-
plementation, and whether their synergy may contribute
to the observed improvements remains unknown and
deserves future controlled studies.
Physical exercise may represent one possible way to
counteract atrophy and fatigue in FSHD but its effects
have not been fully investigated due to concerns that it
may ultimately trigger disease progression. Recent meta
analysis suggests that moderate-intensity strength train-
ing does not appear to harm individuals with FSHD, but
there is insufficient evidence that it provides benefits
[12]. However initial observations have shown that at
least aerobic training is beneficial [13].
The concept that NS might have effects in prevention
or treatment of MD is experiencing a new revival [11].
However the lack of unequivocal results and flaws in the
choice of supplements and protocols to be adopted leads
to an assumption mostly based on empirical attitude.
Among supplements creatine and BCAA may exert posi-
tive effects as they act by limiting load-induced muscle
injury. In particular creatine improves muscle mass and
performance in combination with strength training [14]
and attenuates exercise-induced alteration of markers of
cell death/lysis [15] whereas BCAA may act by maximiz-
ing protein synthesis [4]. Actually, the only creatine trial
in MD, including FSHD, showed a small but significant
improvement of 3% in muscle strength and 10% in daily
life activities [16]. No clinical BCAA trials are currently
available.
These very preliminary indications suggest positive ef-
fects of training and selected supplements in muscle dis-
ease [4], therefore we applied an integrated approach
based on endurance/strength and respiratory training
combined with NS with BCAA and creatine + CLA for
six months.
In this context, here we compared the results of this
approach on physical capacity and blood profile of a 43y
old wheelchair bound FSHD patient with severe prox-
imal and distal muscular impairment, and moderate re-
strictive respiratory insufficiency.
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blood protein profile, body mass and composition, and
an amelioration of peak oxygen consumption whereas
no change in resting energy expenditure was observed.
Furthermore after initiation of the exercise nutrition
intervention, several PFTs demonstrated stable values.
Importantly, the program was well tolerated by the pa-
tient as no muscle soreness, change in CK serum levels
or intolerance to supplements were observed.Limitations of the study
Our study has limitations. The design of the study was
not scientifically sound to answer the questions of which
is the relative contribution of the adopted interventions
to the observed improvements and whether the obtained
results can be reproducible in all FSHD patients or in se-
lected subgroups. Indeed we cannot rule out whether a
possible contribution to the observed changes in body
mass and composition derives by concomitant self-
determined changes in diet lifestyle. Moreover, specific
outcome measures relevant to daily life should be intro-
duced in the study. Notwithstanding these limitations, the
results shown in this paper are novel and may be helpful
to encourage scientists and clinicians to plan more re-
search in this field.Consent
The participant signed a consent approved by which in-
formed the participant that the data would be published
in medical journals without personally identifiable infor-
mation. A copy of the signed informed consent is avail-
able for review upon request.
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